News & Updates
Filter by Specialty:
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
Results from the phase III HARMONi trial presented at WCLC 2025 show that adding ivonescimab to chemotherapy prolongs progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
30 Sep 2025
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
Smoking, obesity, treatment duration, and pre-existing cardiac diseases may contribute to the development of cardiotoxicity among patients with cancer who are undergoing 5-fluorouracil (5-FU) chemotherapy, suggests a recent study.
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
29 Sep 2025
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
29 Sep 2025
Oral methylcobalamin eases hand-foot syndrome in breast cancer patients
The use of oral methylcobalamin is effective in lessening the severity of hand-foot syndrome, without any serious safety concerns, among women with HER2 negative early breast cancer who are treated with adjuvant capecitabine, a study has shown.
